APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Drug Conjugate

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide Drug Conjugate Market Outlook and Growth Opportunities 2026

23 December 2025194 pages

Choose your research edition.

Industry ResearchPeptide Drug Conjugate Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Drug Conjugate Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Peptide Drug Conjugate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Drug Conjugate Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Drug Conjugate Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Peptide Drug Conjugate market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide Drug Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Drug Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Drug Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide Drug Conjugate market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide Drug Conjugate market include Zhongshan Laibo Ruichen Biopharmaceutical, XINOGEN (HONG KONG) PHARMA, Tianjin Conjustar Biotechnology, Lumosa Therapeutics, Shanghai Pharmaceuticals, Shanghai Huiyong Pharmaceutical, Gaorui Yaoye(Beijing)Technologies, BrightGene Bio-Medical Technology and Beijing Shenogen Pharma Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide Drug Conjugate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Drug Conjugate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Drug Conjugate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Drug Conjugate market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Drug Conjugate Segment by Company

Zhongshan Laibo Ruichen Biopharmaceutical

XINOGEN (HONG KONG) PHARMA

Tianjin Conjustar Biotechnology

Lumosa Therapeutics

Shanghai Pharmaceuticals

Shanghai Huiyong Pharmaceutical

Gaorui Yaoye(Beijing)Technologies

BrightGene Bio-Medical Technology

Beijing Shenogen Pharma Group

Theratechnologies

Cybrexa Therapeutics

Bicycle Therapeutics

Peptide Drug Conjugate Segment by Type

Cell Targeting Peptides (CTP)

Cell-penetrating Peptides (CPP)

Others

Peptide Drug Conjugate Segment by Application

Breast Cancer

Pancreatic Cancer

Others

Peptide Drug Conjugate Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide Drug Conjugate status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peptide Drug Conjugate market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide Drug Conjugate significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide Drug Conjugate competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Drug Conjugate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Drug Conjugate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Drug Conjugate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Drug Conjugate market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Drug Conjugate industry.

Chapter 3: Detailed analysis of Peptide Drug Conjugate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peptide Drug Conjugate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peptide Drug Conjugate in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide Drug Conjugate Industry Trends Table 2. Peptide Drug Conjugate Industry Drivers Table 3. Peptide Drug Conjugate Industry Opportunities and Challenges Table 4. Peptide Drug Conjugate Industry Restraints Table 5. Global Peptide Drug Conjugate Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide Drug Conjugate Revenue Share by Company (2021-2026) Table 7. Global Peptide Drug Conjugate Sales Volume by Company (k units) & (2021-2026) Table 8. Global Peptide Drug Conjugate Sales Volume Share by Company (2021-2026) Table 9. Global Peptide Drug Conjugate Average Price (USD/unit) of Company (2021-2026) Table 10. Global Peptide Drug Conjugate Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peptide Drug Conjugate Key Company Manufacturing Base & Headquarters Table 12. Global Peptide Drug Conjugate Company, Product Type & Application Table 13. Global Peptide Drug Conjugate Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Drug Conjugate by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cell Targeting Peptides (CTP) Table 18. Significant Companies of Cell-penetrating Peptides (CPP) Table 19. Significant Companies of Others Table 20. Global Peptide Drug Conjugate Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Peptide Drug Conjugate Sales Volume by Type (2021-2026) & (k units) Table 22. Global Peptide Drug Conjugate Sales Volume by Type (2027-2032) & (k units) Table 23. Global Peptide Drug Conjugate Sales Volume Share by Type (2021-2026) Table 24. Global Peptide Drug Conjugate Sales Volume Share by Type (2027-2032) Table 25. Global Peptide Drug Conjugate Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Peptide Drug Conjugate Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Peptide Drug Conjugate Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Peptide Drug Conjugate Sales Value Share by Type (2021-2026) Table 29. Global Peptide Drug Conjugate Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Breast Cancer Table 31. Significant Companies of Pancreatic Cancer Table 32. Significant Companies of Others Table 33. Global Peptide Drug Conjugate Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Peptide Drug Conjugate Sales Volume by Application (2021-2026) & (k units) Table 35. Global Peptide Drug Conjugate Sales Volume by Application (2027-2032) & (k units) Table 36. Global Peptide Drug Conjugate Sales Volume Share by Application (2021-2026) Table 37. Global Peptide Drug Conjugate Sales Volume Share by Application (2027-2032) Table 38. Global Peptide Drug Conjugate Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Peptide Drug Conjugate Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Peptide Drug Conjugate Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Peptide Drug Conjugate Sales Value Share by Application (2021-2026) Table 42. Global Peptide Drug Conjugate Sales Value Share by Application (2027-2032) Table 43. Global Peptide Drug Conjugate Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Peptide Drug Conjugate Sales by Region (2021-2026) & (k units) Table 45. Global Peptide Drug Conjugate Sales Market Share by Region (2021-2026) Table 46. Global Peptide Drug Conjugate Sales by Region (2027-2032) & (k units) Table 47. Global Peptide Drug Conjugate Sales Market Share by Region (2027-2032) Table 48. Global Peptide Drug Conjugate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Peptide Drug Conjugate Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Peptide Drug Conjugate Sales Value Share by Region (2021-2026) Table 51. Global Peptide Drug Conjugate Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Peptide Drug Conjugate Sales Value Share by Region (2027-2032) Table 53. Global Peptide Drug Conjugate Market Average Price (USD/unit) by Region (2021-2026) Table 54. Global Peptide Drug Conjugate Market Average Price (USD/unit) by Region (2027-2032) Table 55. Global Peptide Drug Conjugate Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Peptide Drug Conjugate Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Peptide Drug Conjugate Sales by Country (2021-2026) & (k units) Table 58. Global Peptide Drug Conjugate Sales Market Share by Country (2021-2026) Table 59. Global Peptide Drug Conjugate Sales by Country (2027-2032) & (k units) Table 60. Global Peptide Drug Conjugate Sales Market Share by Country (2027-2032) Table 61. Global Peptide Drug Conjugate Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Peptide Drug Conjugate Sales Value Market Share by Country (2021-2026) Table 63. Global Peptide Drug Conjugate Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Peptide Drug Conjugate Sales Value Market Share by Country (2027-2032) Table 65. Zhongshan Laibo Ruichen Biopharmaceutical Company Information Table 66. Zhongshan Laibo Ruichen Biopharmaceutical Business Overview Table 67. Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 68. Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Portfolio Table 69. Zhongshan Laibo Ruichen Biopharmaceutical Recent Development Table 70. XINOGEN (HONG KONG) PHARMA Company Information Table 71. XINOGEN (HONG KONG) PHARMA Business Overview Table 72. XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 73. XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Portfolio Table 74. XINOGEN (HONG KONG) PHARMA Recent Development Table 75. Tianjin Conjustar Biotechnology Company Information Table 76. Tianjin Conjustar Biotechnology Business Overview Table 77. Tianjin Conjustar Biotechnology Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 78. Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Portfolio Table 79. Tianjin Conjustar Biotechnology Recent Development Table 80. Lumosa Therapeutics Company Information Table 81. Lumosa Therapeutics Business Overview Table 82. Lumosa Therapeutics Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 83. Lumosa Therapeutics Peptide Drug Conjugate Product Portfolio Table 84. Lumosa Therapeutics Recent Development Table 85. Shanghai Pharmaceuticals Company Information Table 86. Shanghai Pharmaceuticals Business Overview Table 87. Shanghai Pharmaceuticals Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. Shanghai Pharmaceuticals Peptide Drug Conjugate Product Portfolio Table 89. Shanghai Pharmaceuticals Recent Development Table 90. Shanghai Huiyong Pharmaceutical Company Information Table 91. Shanghai Huiyong Pharmaceutical Business Overview Table 92. Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Portfolio Table 94. Shanghai Huiyong Pharmaceutical Recent Development Table 95. Gaorui Yaoye(Beijing)Technologies Company Information Table 96. Gaorui Yaoye(Beijing)Technologies Business Overview Table 97. Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Portfolio Table 99. Gaorui Yaoye(Beijing)Technologies Recent Development Table 100. BrightGene Bio-Medical Technology Company Information Table 101. BrightGene Bio-Medical Technology Business Overview Table 102. BrightGene Bio-Medical Technology Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Portfolio Table 104. BrightGene Bio-Medical Technology Recent Development Table 105. Beijing Shenogen Pharma Group Company Information Table 106. Beijing Shenogen Pharma Group Business Overview Table 107. Beijing Shenogen Pharma Group Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Portfolio Table 109. Beijing Shenogen Pharma Group Recent Development Table 110. Theratechnologies Company Information Table 111. Theratechnologies Business Overview Table 112. Theratechnologies Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Theratechnologies Peptide Drug Conjugate Product Portfolio Table 114. Theratechnologies Recent Development Table 115. Cybrexa Therapeutics Company Information Table 116. Cybrexa Therapeutics Business Overview Table 117. Cybrexa Therapeutics Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Cybrexa Therapeutics Peptide Drug Conjugate Product Portfolio Table 119. Cybrexa Therapeutics Recent Development Table 120. Bicycle Therapeutics Company Information Table 121. Bicycle Therapeutics Business Overview Table 122. Bicycle Therapeutics Peptide Drug Conjugate Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Bicycle Therapeutics Peptide Drug Conjugate Product Portfolio Table 124. Bicycle Therapeutics Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Peptide Drug Conjugate Distributors List Table 128. Peptide Drug Conjugate Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Peptide Drug Conjugate Product Image Figure 2. Global Peptide Drug Conjugate Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Drug Conjugate Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peptide Drug Conjugate Sales (2021-2032) & (k units) Figure 5. Global Peptide Drug Conjugate Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Peptide Drug Conjugate Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cell Targeting Peptides (CTP) Image Figure 10. Cell-penetrating Peptides (CPP) Image Figure 11. Others Image Figure 12. Global Peptide Drug Conjugate Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Peptide Drug Conjugate Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Peptide Drug Conjugate Sales Volume Share by Type (2021-2032) Figure 15. Global Peptide Drug Conjugate Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Peptide Drug Conjugate Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Peptide Drug Conjugate Sales Value Share by Type (2021-2032) Figure 18. Breast Cancer Image Figure 19. Pancreatic Cancer Image Figure 20. Others Image Figure 21. Global Peptide Drug Conjugate Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Peptide Drug Conjugate Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Peptide Drug Conjugate Sales Volume Share by Application (2021-2032) Figure 24. Global Peptide Drug Conjugate Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Peptide Drug Conjugate Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Peptide Drug Conjugate Sales Value Share by Application (2021-2032) Figure 27. Global Peptide Drug Conjugate Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Peptide Drug Conjugate Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Peptide Drug Conjugate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Peptide Drug Conjugate Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Peptide Drug Conjugate Sales Value (2021-2032) & (US$ Million) Figure 32. North America Peptide Drug Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Peptide Drug Conjugate Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Peptide Drug Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Peptide Drug Conjugate Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Peptide Drug Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Peptide Drug Conjugate Sales Value (2021-2032) & (US$ Million) Figure 38. South America Peptide Drug Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Peptide Drug Conjugate Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Peptide Drug Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Peptide Drug Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Peptide Drug Conjugate Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Peptide Drug Conjugate Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Targeting Peptides (CTP)
  • Cell-penetrating Peptides (CPP)
  • Others
Applications
  • Breast Cancer
  • Pancreatic Cancer
  • Others
Companies covered
  • Zhongshan Laibo Ruichen Biopharmaceutical
  • XINOGEN (HONG KONG) PHARMA
  • Tianjin Conjustar Biotechnology
  • Lumosa Therapeutics
  • Shanghai Pharmaceuticals
  • Shanghai Huiyong Pharmaceutical
  • Gaorui Yaoye(Beijing)Technologies
  • BrightGene Bio-Medical Technology
  • Beijing Shenogen Pharma Group
  • Theratechnologies
  • Cybrexa Therapeutics
  • Bicycle Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide Drug Conjugate Sales Value (2021-2032)
  4. 1.2.2 Global Peptide Drug Conjugate Sales Volume (2021-2032)
  5. 1.2.3 Global Peptide Drug Conjugate Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peptide Drug Conjugate Market Dynamics
  1. 2.1 Peptide Drug Conjugate Industry Trends
  2. 2.2 Peptide Drug Conjugate Industry Drivers
  3. 2.3 Peptide Drug Conjugate Industry Opportunities and Challenges
  4. 2.4 Peptide Drug Conjugate Industry Restraints
3 Peptide Drug Conjugate Market by Company
  1. 3.1 Global Peptide Drug Conjugate Company Revenue Ranking in 2025
  2. 3.2 Global Peptide Drug Conjugate Revenue by Company (2021-2026)
  3. 3.3 Global Peptide Drug Conjugate Sales Volume by Company (2021-2026)
  4. 3.4 Global Peptide Drug Conjugate Average Price by Company (2021-2026)
  5. 3.5 Global Peptide Drug Conjugate Company Ranking (2024-2026)
  6. 3.6 Global Peptide Drug Conjugate Company Manufacturing Base and Headquarters
  7. 3.7 Global Peptide Drug Conjugate Company Product Type and Application
  8. 3.8 Global Peptide Drug Conjugate Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peptide Drug Conjugate Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peptide Drug Conjugate Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peptide Drug Conjugate Market by Type
  1. 4.1 Peptide Drug Conjugate Type Introduction
  2. 4.1.1 Cell Targeting Peptides (CTP)
  3. 4.1.2 Cell-penetrating Peptides (CPP)
  4. 4.1.3 Others
  5. 4.2 Global Peptide Drug Conjugate Sales Volume by Type
  6. 4.2.1 Global Peptide Drug Conjugate Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide Drug Conjugate Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Peptide Drug Conjugate Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Peptide Drug Conjugate Sales Value by Type
  10. 4.3.1 Global Peptide Drug Conjugate Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Peptide Drug Conjugate Sales Value by Type (2021-2032)
  12. 4.3.3 Global Peptide Drug Conjugate Sales Value Share by Type (2021-2032)
5 Peptide Drug Conjugate Market by Application
  1. 5.1 Peptide Drug Conjugate Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Pancreatic Cancer
  4. 5.1.3 Others
  5. 5.2 Global Peptide Drug Conjugate Sales Volume by Application
  6. 5.2.1 Global Peptide Drug Conjugate Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide Drug Conjugate Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Peptide Drug Conjugate Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Peptide Drug Conjugate Sales Value by Application
  10. 5.3.1 Global Peptide Drug Conjugate Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peptide Drug Conjugate Sales Value by Application (2021-2032)
  12. 5.3.3 Global Peptide Drug Conjugate Sales Value Share by Application (2021-2032)
6 Peptide Drug Conjugate Regional Sales and Value Analysis
  1. 6.1 Global Peptide Drug Conjugate Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Drug Conjugate Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Drug Conjugate Sales by Region: 2021-2026
  4. 6.2.2 Global Peptide Drug Conjugate Sales by Region (2027-2032)
  5. 6.3 Global Peptide Drug Conjugate Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peptide Drug Conjugate Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peptide Drug Conjugate Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peptide Drug Conjugate Sales Value by Region (2027-2032)
  9. 6.5 Global Peptide Drug Conjugate Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peptide Drug Conjugate Sales Value (2021-2032)
  12. 6.6.2 North America Peptide Drug Conjugate Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peptide Drug Conjugate Sales Value (2021-2032)
  15. 6.7.2 Europe Peptide Drug Conjugate Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peptide Drug Conjugate Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peptide Drug Conjugate Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peptide Drug Conjugate Sales Value (2021-2032)
  21. 6.9.2 South America Peptide Drug Conjugate Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peptide Drug Conjugate Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peptide Drug Conjugate Sales Value Share by Country, 2025 VS 2032
7 Peptide Drug Conjugate Country-level Sales and Value Analysis
  1. 7.1 Global Peptide Drug Conjugate Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide Drug Conjugate Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peptide Drug Conjugate Sales by Country (2021-2032)
  4. 7.3.1 Global Peptide Drug Conjugate Sales by Country (2021-2026)
  5. 7.3.2 Global Peptide Drug Conjugate Sales by Country (2027-2032)
  6. 7.4 Global Peptide Drug Conjugate Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peptide Drug Conjugate Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peptide Drug Conjugate Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peptide Drug Conjugate Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peptide Drug Conjugate Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peptide Drug Conjugate Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhongshan Laibo Ruichen Biopharmaceutical
  2. 8.1.1 Zhongshan Laibo Ruichen Biopharmaceutical Company Information
  3. 8.1.2 Zhongshan Laibo Ruichen Biopharmaceutical Business Overview
  4. 8.1.3 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Portfolio
  6. 8.1.5 Zhongshan Laibo Ruichen Biopharmaceutical Recent Developments
  7. 8.2 XINOGEN (HONG KONG) PHARMA
  8. 8.2.1 XINOGEN (HONG KONG) PHARMA Company Information
  9. 8.2.2 XINOGEN (HONG KONG) PHARMA Business Overview
  10. 8.2.3 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Portfolio
  12. 8.2.5 XINOGEN (HONG KONG) PHARMA Recent Developments
  13. 8.3 Tianjin Conjustar Biotechnology
  14. 8.3.1 Tianjin Conjustar Biotechnology Company Information
  15. 8.3.2 Tianjin Conjustar Biotechnology Business Overview
  16. 8.3.3 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Portfolio
  18. 8.3.5 Tianjin Conjustar Biotechnology Recent Developments
  19. 8.4 Lumosa Therapeutics
  20. 8.4.1 Lumosa Therapeutics Company Information
  21. 8.4.2 Lumosa Therapeutics Business Overview
  22. 8.4.3 Lumosa Therapeutics Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lumosa Therapeutics Peptide Drug Conjugate Product Portfolio
  24. 8.4.5 Lumosa Therapeutics Recent Developments
  25. 8.5 Shanghai Pharmaceuticals
  26. 8.5.1 Shanghai Pharmaceuticals Company Information
  27. 8.5.2 Shanghai Pharmaceuticals Business Overview
  28. 8.5.3 Shanghai Pharmaceuticals Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai Pharmaceuticals Peptide Drug Conjugate Product Portfolio
  30. 8.5.5 Shanghai Pharmaceuticals Recent Developments
  31. 8.6 Shanghai Huiyong Pharmaceutical
  32. 8.6.1 Shanghai Huiyong Pharmaceutical Company Information
  33. 8.6.2 Shanghai Huiyong Pharmaceutical Business Overview
  34. 8.6.3 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Portfolio
  36. 8.6.5 Shanghai Huiyong Pharmaceutical Recent Developments
  37. 8.7 Gaorui Yaoye(Beijing)Technologies
  38. 8.7.1 Gaorui Yaoye(Beijing)Technologies Company Information
  39. 8.7.2 Gaorui Yaoye(Beijing)Technologies Business Overview
  40. 8.7.3 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Portfolio
  42. 8.7.5 Gaorui Yaoye(Beijing)Technologies Recent Developments
  43. 8.8 BrightGene Bio-Medical Technology
  44. 8.8.1 BrightGene Bio-Medical Technology Company Information
  45. 8.8.2 BrightGene Bio-Medical Technology Business Overview
  46. 8.8.3 BrightGene Bio-Medical Technology Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Portfolio
  48. 8.8.5 BrightGene Bio-Medical Technology Recent Developments
  49. 8.9 Beijing Shenogen Pharma Group
  50. 8.9.1 Beijing Shenogen Pharma Group Company Information
  51. 8.9.2 Beijing Shenogen Pharma Group Business Overview
  52. 8.9.3 Beijing Shenogen Pharma Group Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Portfolio
  54. 8.9.5 Beijing Shenogen Pharma Group Recent Developments
  55. 8.10 Theratechnologies
  56. 8.10.1 Theratechnologies Company Information
  57. 8.10.2 Theratechnologies Business Overview
  58. 8.10.3 Theratechnologies Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Theratechnologies Peptide Drug Conjugate Product Portfolio
  60. 8.10.5 Theratechnologies Recent Developments
  61. 8.11 Cybrexa Therapeutics
  62. 8.11.1 Cybrexa Therapeutics Company Information
  63. 8.11.2 Cybrexa Therapeutics Business Overview
  64. 8.11.3 Cybrexa Therapeutics Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Cybrexa Therapeutics Peptide Drug Conjugate Product Portfolio
  66. 8.11.5 Cybrexa Therapeutics Recent Developments
  67. 8.12 Bicycle Therapeutics
  68. 8.12.1 Bicycle Therapeutics Company Information
  69. 8.12.2 Bicycle Therapeutics Business Overview
  70. 8.12.3 Bicycle Therapeutics Peptide Drug Conjugate Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bicycle Therapeutics Peptide Drug Conjugate Product Portfolio
  72. 8.12.5 Bicycle Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Drug Conjugate Value Chain Analysis
  2. 9.1.1 Peptide Drug Conjugate Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Drug Conjugate Sales Mode & Process
  6. 9.2 Peptide Drug Conjugate Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Drug Conjugate Distributors
  9. 9.2.3 Peptide Drug Conjugate Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst